TipRanks
Advertisement
Advertisement

PCCYTOR Stock Latest News

CytoReason Emphasizes Tools‑Based Model for Data‑Driven Drug Development
Private CompaniesCytoReason Emphasizes Tools‑Based Model for Data‑Driven Drug Development
3h ago
CYTOR
CytoReason Marks 10 Years With Strategic Focus on AI-Driven Disease Modeling
PremiumPrivate Companies
CytoReason Marks 10 Years With Strategic Focus on AI-Driven Disease Modeling
1d ago
CYTOR
CytoReason Marks 10-Year Milestone While Emphasizing Specialized AI for Pharma Decision-Making
PremiumPrivate Companies
CytoReason Marks 10-Year Milestone While Emphasizing Specialized AI for Pharma Decision-Making
2d ago
CYTOR
CytoReason Strengthens Commercial Team With New Business Development VP
PremiumPrivate Companies
CytoReason Strengthens Commercial Team With New Business Development VP
9d ago
CYTOR
CytoReason Highlights Inflammatory Disease Modeling Capabilities and Business Development Focus
PremiumPrivate Companies
CytoReason Highlights Inflammatory Disease Modeling Capabilities and Business Development Focus
15d ago
CYTOR
CytoReason Strengthens Commercial Leadership With New Chief Commercial Officer
PremiumPrivate CompaniesCytoReason Strengthens Commercial Leadership With New Chief Commercial Officer
17d ago
CYTOR
Cultural Focus And Talent Development Underscore CytoReason’s Long-Term Positioning
Premium
Private Companies
Cultural Focus And Talent Development Underscore CytoReason’s Long-Term Positioning
1M ago
CYTOR
CytoReason Strengthens Scientific Advisory Board With AI and Data Leader
Premium
Private Companies
CytoReason Strengthens Scientific Advisory Board With AI and Data Leader
1M ago
CYTOR
Disease Biology Insights Highlight Psoriasis Comorbidities and R&D Focus
PremiumPrivate Companies
Disease Biology Insights Highlight Psoriasis Comorbidities and R&D Focus
2M ago
CYTOR
CytoReason Bolsters Advisory Board and Showcases Role of Disease Models in Biopharma R&D
PremiumPrivate Companies
CytoReason Bolsters Advisory Board and Showcases Role of Disease Models in Biopharma R&D
3M ago
CYTOR
CytoReason Strengthens Clinical Advisory Board With Dermatology Expert
PremiumPrivate Companies
CytoReason Strengthens Clinical Advisory Board With Dermatology Expert
3M ago
CYTOR
CytoReason Highlights Computational Disease Models for Biopharma R&D Decisions
PremiumPrivate Companies
CytoReason Highlights Computational Disease Models for Biopharma R&D Decisions
3M ago
CYTOR
CytoReason Expands Asia-Pacific Reach as It Advances AI-Driven R&D Capabilities
PremiumPrivate CompaniesCytoReason Expands Asia-Pacific Reach as It Advances AI-Driven R&D Capabilities
3M ago
CYTOR
CytoReason Explores Asia-Pacific Opportunities Through Korean Biopharma Engagement
Premium
Private Companies
CytoReason Explores Asia-Pacific Opportunities Through Korean Biopharma Engagement
3M ago
CYTOR
CytoReason – Weekly Recap
Premium
Private Companies
CytoReason – Weekly Recap
3M ago
CYTOR
CytoReason Highlights AI-Driven Innovation Through Internal Hackathon
PremiumPrivate Companies
CytoReason Highlights AI-Driven Innovation Through Internal Hackathon
4M ago
CYTOR
CytoReason – Weekly Recap
PremiumPrivate Companies
CytoReason – Weekly Recap
4M ago
CYTOR
CytoReason Showcases AI Disease Models in Collaboration with Sanofi at VivaTech
PremiumPrivate Companies
CytoReason Showcases AI Disease Models in Collaboration with Sanofi at VivaTech
4M ago
CYTOR
CytoReason Hosts HealthTech Women Executive Networking Event
PremiumPrivate Companies
CytoReason Hosts HealthTech Women Executive Networking Event
4M ago
CYTOR
CytoReason Showcases Computational Disease Models with Sanofi at VivaTech 2026
PremiumPrivate CompaniesCytoReason Showcases Computational Disease Models with Sanofi at VivaTech 2026
4M ago
CYTOR
CytoReason – Weekly Recap
Premium
Private Companies
CytoReason – Weekly Recap
5M ago
CYTOR
Biopharma Partner Visibility Highlights CytoReason’s Role in Portfolio Decision-Making
Premium
Private Companies
Biopharma Partner Visibility Highlights CytoReason’s Role in Portfolio Decision-Making
5M ago
CYTOR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >